Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?

Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?

Pancreatic ductal adenocarcinoma (PDAC) has an aggressive tumor biology and is associated with poor survival outcomes. Most patients present with metastatic or locally advanced disease. In the 10–20% of patients with upfront resectable disease, surgery offers the only chance of cure, with the additi...

Full description

Bibliographic Details
Main Authors: Shelize Khakoo, Angelica Petrillo, Massimiliano Salati, Abdul Muhith, Jessica Evangelista, Silvia Seghezzi, Fausto Petrelli, Gianluca Tomasello, Michele Ghidini
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
pancreatic ductal adenocarcinoma
neo-adjuvant chemotherapy
radiotherapy
immunotherapy
biomarkers
resectability
Online Access:https://www.mdpi.com/2072-6694/13/17/4396

Similar Items

Similar Items